Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma

NCT02551237 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02551237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02551237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
January 7, 2016
Completion date
June 30, 2022
Enrollment
103 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

rectal carcinoma